Biocept (BIOC) Lifted to Buy at ValuEngine

ValuEngine upgraded shares of Biocept (NASDAQ:BIOC) from a hold rating to a buy rating in a report released on Thursday morning.

BIOC has been the topic of a number of other research reports. Dawson James restated a buy rating on shares of Biocept in a report on Wednesday, October 3rd. Zacks Investment Research upgraded Biocept from a sell rating to a hold rating in a report on Monday, August 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Biocept presently has a consensus rating of Hold and an average target price of $0.92.

Biocept stock traded down $0.03 during mid-day trading on Thursday, reaching $1.98. The stock had a trading volume of 75,790 shares, compared to its average volume of 319,259. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.20 and a quick ratio of 1.08. Biocept has a fifty-two week low of $1.89 and a fifty-two week high of $36.00.

Biocept (NASDAQ:BIOC) last posted its earnings results on Tuesday, August 14th. The medical research company reported ($2.70) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.30) by $0.60. Biocept had a negative return on equity of 587.80% and a negative net margin of 642.49%. The company had revenue of $0.82 million for the quarter, compared to analyst estimates of $1.09 million. As a group, sell-side analysts predict that Biocept will post -9.05 earnings per share for the current year.

A hedge fund recently raised its stake in Biocept stock. BlackRock Inc. grew its stake in Biocept Inc (NASDAQ:BIOC) by 1.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 794,302 shares of the medical research company’s stock after purchasing an additional 14,403 shares during the quarter. BlackRock Inc. owned approximately 34.99% of Biocept worth $159,000 at the end of the most recent reporting period.

About Biocept

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Featured Story: Bear Market

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.

Leave a Reply